Unfortunately, these pharmacologic therapies are associated with many deleterious side effects, including peripheral edema, Cushing syndrome, fatigue, hyperglycemia, thromboembolism, and, in particular, severe skeletal muscle catabolism. Collectively, these side-effects which can have a profound impact on a patient's quality of life (QOL) and physical functioning/performance status. Performance status has been consistently demonstrated to be a strong independent predictor of morbidity and mortality in patients with neurologic malignancies. Clearly, supportive interventions that attenuate therapy-induced functional declines may have substantial clinical benefits for this population.